{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:26:36Z","timestamp":1791897996793,"version":"4.3.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K08339"],"award-info":[{"award-number":["20K08339"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K07360"],"award-info":[{"award-number":["23K07360"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Biofilms Microbiomes"],"DOI":"10.1038\/s41522-024-00564-y","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T06:02:16Z","timestamp":1726466536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Akkermansia muciniphila in the small intestine improves liver fibrosis in a murine liver cirrhosis model"],"prefix":"10.1038","volume":"10","author":[{"given":"Noriaki","family":"Oguri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuu","family":"Nishinarita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuki","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritaka","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8927-4417","authenticated-orcid":false,"given":"Sawako","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8073-989X","authenticated-orcid":false,"given":"Sonny T. M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6430-4666","authenticated-orcid":false,"given":"Takako","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-3536","authenticated-orcid":false,"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"564_CR1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang, D. Q. et al. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat. Rev. Gastroenterol. Hepatol. 20, 388\u2013398 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"564_CR2","unstructured":"The Global Health Observatory. Global health estimates: leading causes of death. WHO https:\/\/www.who.int\/data\/gho\/data\/themes\/mortality-and-global-health-estimates\/ghe-leading-causes-of-death (2023)."},{"key":"564_CR3","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin, P. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381, 468\u2013475 (2013).","journal-title":"Lancet"},{"key":"564_CR4","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/hep.29009","volume":"65","author":"Y Sun","year":"2017","unstructured":"Sun, Y. et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology 65, 1438\u20131450 (2017).","journal-title":"Hepatology"},{"key":"564_CR5","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/hep.23809","volume":"52","author":"PJ Pockros","year":"2010","unstructured":"Pockros, P. J. et al. Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology 52, 1193\u20131200 (2010).","journal-title":"Hepatology"},{"key":"564_CR6","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/hep.29557","volume":"67","author":"E Mauro","year":"2018","unstructured":"Mauro, E. et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology 67, 1683\u20131694 (2018).","journal-title":"Hepatology"},{"key":"564_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hep.27210","volume":"60","author":"H Vilstrup","year":"2014","unstructured":"Vilstrup, H. et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60, 715\u2013735 (2014).","journal-title":"Hepatology"},{"key":"564_CR8","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1016\/j.cgh.2015.06.039","volume":"13","author":"KR Patidar","year":"2015","unstructured":"Patidar, K. R. & Bajaj, J. S. Covert and overt hepatic encephalopathy: diagnosis and management. Clin. Gastroenterol. Hepatol. 13, 2048\u20132061 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"564_CR9","doi-asserted-by":"crossref","unstructured":"EASL. Clinical practice guidelines on nutrition in chronic liver disease. J. Hepatol. 70, 172\u2013193 (2019).","DOI":"10.1016\/j.jhep.2018.06.024"},{"key":"564_CR10","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1007\/s10620-019-05576-9","volume":"64","author":"G Hirode","year":"2019","unstructured":"Hirode, G., Vittinghoff, E. & Wong, R. J. Increasing burden of hepatic encephalopathy among hospitalized adults: an analysis of the 2010-2014 national inpatient sample. Dig. Dis. Sci. 64, 1448\u20131457 (2019).","journal-title":"Dig. Dis. Sci."},{"key":"564_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jhep.2013.10.004","volume":"60","author":"J Cordoba","year":"2014","unstructured":"Cordoba, J. et al. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J. Hepatol. 60, 275\u2013281 (2014).","journal-title":"J. Hepatol."},{"key":"564_CR12","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/hep.23500","volume":"51","author":"P Jepsen","year":"2010","unstructured":"Jepsen, P., Ott, P., Andersen, P. K., S\u00f8rensen, H. T. & Vilstrup, H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 51, 1675\u20131682 (2010).","journal-title":"Hepatology"},{"key":"564_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.cgh.2015.11.007","volume":"14","author":"MM Lauridsen","year":"2016","unstructured":"Lauridsen, M. M. et al. In patients with cirrhosis, driving simulator performance is associated with real-life driving. Clin. Gastroenterol. Hepatol. 14, 747\u2013752 (2016).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"564_CR14","doi-asserted-by":"crossref","unstructured":"Faccioli, J., Nardelli, S., Gioia, S., Riggio, O. & Ridola, L. Minimal hepatic encephalopathy affects daily life of cirrhotic patients: a viewpoint on clinical consequences and therapeutic opportunities. J. Clin. Med. 11, 7246\u20137263 (2022).","DOI":"10.3390\/jcm11237246"},{"key":"564_CR15","doi-asserted-by":"crossref","unstructured":"San Mart\u00edn-Valenzuela, C. et al. Motor and cognitive performance in patients with liver cirrhosis with minimal hepatic encephalopathy. J. Clin. Med. 9, 2154\u20132169 (2020).","DOI":"10.3390\/jcm9072154"},{"key":"564_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3350\/cmh.2012.18.4.337","volume":"18","author":"YS Seo","year":"2012","unstructured":"Seo, Y. S. & Shah, V. H. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin. Mol. Hepatol. 18, 337\u2013346 (2012).","journal-title":"Clin. Mol. Hepatol."},{"key":"564_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.4254\/wjh.v7.i3.425","volume":"7","author":"H Fukui","year":"2015","unstructured":"Fukui, H. Gut-liver axis in liver cirrhosis: how to manage leaky gut and endotoxemia. World J. Hepatol. 7, 425\u2013442 (2015).","journal-title":"World J. Hepatol."},{"key":"564_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature13568","volume":"513","author":"N Qin","year":"2014","unstructured":"Qin, N. et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513, 59\u201364 (2014).","journal-title":"Nature"},{"key":"564_CR19","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","volume":"60","author":"JS Bajaj","year":"2014","unstructured":"Bajaj, J. S. et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J. Hepatol. 60, 940\u2013947 (2014).","journal-title":"J. Hepatol."},{"key":"564_CR20","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/hep.24423","volume":"54","author":"Y Chen","year":"2011","unstructured":"Chen, Y. et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54, 562\u2013572 (2011).","journal-title":"Hepatology"},{"key":"564_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1055\/s-0037-1602763","volume":"37","author":"BC Davis","year":"2017","unstructured":"Davis, B. C. & Bajaj, J. S. The human gut microbiome in liver diseases. Semin. Liver Dis. 37, 128\u2013140 (2017).","journal-title":"Semin. Liver Dis."},{"key":"564_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11011-012-9370-2","volume":"28","author":"TH Tranah","year":"2013","unstructured":"Tranah, T. H., Vijay, G. K., Ryan, J. M. & Shawcross, D. L. Systemic inflammation and ammonia in hepatic encephalopathy. Metab. Brain Dis. 28, 1\u20135 (2013).","journal-title":"Metab. Brain Dis."},{"key":"564_CR23","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/ajg.2013.219","volume":"108","author":"BC Sharma","year":"2013","unstructured":"Sharma, B. C. et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am. J. Gastroenterol. 108, 1458\u20131463 (2013).","journal-title":"Am. J. Gastroenterol."},{"key":"564_CR24","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","volume":"362","author":"NM Bass","year":"2010","unstructured":"Bass, N. M. et al. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 362, 1071\u20131081 (2010).","journal-title":"N. Engl. J. Med."},{"key":"564_CR25","doi-asserted-by":"crossref","unstructured":"Ojetti, V. et al. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol. 5, 675\u2013682 (2009).","DOI":"10.1517\/17425250902973695"},{"key":"564_CR26","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1128\/AAC.00691-09","volume":"54","author":"EL Brown","year":"2010","unstructured":"Brown, E. L., Xue, Q., Jiang, Z. D., Xu, Y. & Dupont, H. L. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob. Agents Chemother. 54, 388\u2013396 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"564_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068550","volume":"8","author":"C Schrodt","year":"2013","unstructured":"Schrodt, C., McHugh, E. E., Gawinowicz, M. A., Dupont, H. L. & Brown, E. L. Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysis. PLoS ONE 8, e68550 (2013).","journal-title":"PLoS ONE"},{"key":"564_CR28","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1038\/ctg.2016.44","volume":"7","author":"DJ Kang","year":"2016","unstructured":"Kang, D. J. et al. Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition. Clin. Transl. Gastroenterol. 7, e187 (2016).","journal-title":"Clin. Transl. Gastroenterol."},{"key":"564_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1124\/pr.118.015768","volume":"71","author":"G Clarke","year":"2019","unstructured":"Clarke, G. et al. Gut reactions: breaking down xenobiotic-microbiome interactions. Pharmacol. Rev. 71, 198\u2013224 (2019).","journal-title":"Pharmacol. Rev."},{"key":"564_CR30","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/hep.20452","volume":"40","author":"I Sakaida","year":"2004","unstructured":"Sakaida, I. et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 40, 1304\u20131311 (2004).","journal-title":"Hepatology"},{"key":"564_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa, L. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat. Med. 28, 315\u2013324 (2022).","journal-title":"Nat. Med."},{"key":"564_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02427-7","volume":"22","author":"N Karcher","year":"2021","unstructured":"Karcher, N. et al. Genomic diversity and ecology of human-associated Akkermansia species in the gut microbiome revealed by extensive metagenomic assembly. Genome Biol. 22, 209 (2021).","journal-title":"Genome Biol."},{"key":"564_CR33","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1080\/19490976.2020.1737307","volume":"11","author":"C Depommier","year":"2020","unstructured":"Depommier, C. et al. Pasteurized Akkermansia muciniphila increases whole-body energy expenditure and fecal energy excretion in diet-induced obese mice. Gut Microbes 11, 1231\u20131245 (2020).","journal-title":"Gut Microbes"},{"key":"564_CR34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nm.4236","volume":"23","author":"H Plovier","year":"2017","unstructured":"Plovier, H. et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 23, 107\u2013113 (2017).","journal-title":"Nat. Med."},{"key":"564_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2017.12.001","volume":"68","author":"V Ratziu","year":"2018","unstructured":"Ratziu, V. A critical review of endpoints for non-cirrhotic NASH therapeutic trials. J. Hepatol. 68, 353\u2013361 (2018).","journal-title":"J. Hepatol."},{"key":"564_CR36","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw, Y. F. et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351, 1521\u20131531 (2004).","journal-title":"N. Engl. J. Med."},{"key":"564_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-016-0181-2","volume":"4","author":"KL Ormerod","year":"2016","unstructured":"Ormerod, K. L. et al. Genomic characterization of the uncultured Bacteroidales family S24-7 inhabiting the guts of homeothermic animals. Microbiome 4, 36 (2016).","journal-title":"Microbiome"},{"key":"564_CR38","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41564-019-0649-5","volume":"5","author":"E Zagato","year":"2020","unstructured":"Zagato, E. et al. Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. Nat. Microbiol. 5, 511\u2013524 (2020).","journal-title":"Nat. Microbiol."},{"key":"564_CR39","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.chom.2022.07.015","volume":"30","author":"YG Cao","year":"2022","unstructured":"Cao, Y. G. et al. Faecalibaculum rodentium remodels retinoic acid signaling to govern eosinophil-dependent intestinal epithelial homeostasis. Cell Host Microbe 30, 1295\u20131310.e1298 (2022).","journal-title":"Cell Host Microbe"},{"key":"564_CR40","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1038\/ajg.2010.281","volume":"105","author":"CW Png","year":"2010","unstructured":"Png, C. W. et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am. J. Gastroenterol. 105, 2420\u20132428 (2010).","journal-title":"Am. J. Gastroenterol."},{"key":"564_CR41","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1099\/mic.0.000444","volume":"163","author":"WM de Vos","year":"2017","unstructured":"de Vos, W. M. Microbe Profile: Akkermansia muciniphila: a conserved intestinal symbiont that acts as the gatekeeper of our mucosa. Microbiology 163, 646\u2013648 (2017).","journal-title":"Microbiology"},{"key":"564_CR42","doi-asserted-by":"crossref","unstructured":"Yang, J., Yang, H. & Li, Y. The triple interactions between gut microbiota, mycobiota and host immunity. Crit. Rev. Food Sci. Nutr. 63, 11604\u201311624 (2023).","DOI":"10.1080\/10408398.2022.2094888"},{"key":"564_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/srep16643","volume":"5","author":"M Schneeberger","year":"2015","unstructured":"Schneeberger, M. et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci. Rep. 5, 16643 (2015).","journal-title":"Sci. Rep."},{"key":"564_CR44","doi-asserted-by":"publisher","first-page":"9066","DOI":"10.1073\/pnas.1219451110","volume":"110","author":"A Everard","year":"2013","unstructured":"Everard, A. et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl Acad. Sci. USA 110, 9066\u20139071 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"564_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.725583","volume":"12","author":"X Hou","year":"2021","unstructured":"Hou, X. et al. Akkermansia Muciniphila potentiates the antitumor efficacy of FOLFOX in colon cancer. Front. Pharmacol. 12, 725583 (2021).","journal-title":"Front. Pharmacol."},{"key":"564_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00730-21","volume":"9","author":"S Qu","year":"2021","unstructured":"Qu, S. et al. Akkermansia muciniphila alleviates dextran sulfate sodium (DSS)-induced acute colitis by NLRP3 activation. Microbiol. Spectr. 9, e0073021 (2021).","journal-title":"Microbiol. Spectr."},{"key":"564_CR47","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00484-21","volume":"9","author":"S Keshavarz Azizi Raftar","year":"2021","unstructured":"Keshavarz Azizi Raftar, S. et al. The protective effects of live and pasteurized Akkermansia muciniphila and its extracellular vesicles against HFD\/CCl4-induced liver injury. Microbiol. Spectr. 9, e0048421 (2021).","journal-title":"Microbiol. Spectr."},{"key":"564_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06414-1","volume":"12","author":"SKA Raftar","year":"2022","unstructured":"Raftar, S. K. A. et al. The anti-inflammatory effects of Akkermansia muciniphila and its derivates in HFD\/CCL4-induced murine model of liver injury. Sci. Rep. 12, 2453 (2022).","journal-title":"Sci. Rep."},{"key":"564_CR49","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1136\/gutjnl-2016-313432","volume":"67","author":"C Grander","year":"2018","unstructured":"Grander, C. et al. Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease. Gut 67, 891\u2013901 (2018).","journal-title":"Gut"},{"key":"564_CR50","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/17474124.2019.1569513","volume":"13","author":"KT Suk","year":"2019","unstructured":"Suk, K. T. & Kim, D. J. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol. 13, 193\u2013204 (2019).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"564_CR51","doi-asserted-by":"publisher","first-page":"G490","DOI":"10.1152\/ajpgi.00120.2012","volume":"303","author":"E Im","year":"2012","unstructured":"Im, E., Riegler, F. M., Pothoulakis, C. & Rhee, S. H. Elevated lipopolysaccharide in the colon evokes intestinal inflammation, aggravated in immune modulator-impaired mice. Am. J. Physiol. Gastrointest. Liver Physiol. 303, G490\u2013G497 (2012).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"564_CR52","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/gutjnl-2017-314508","volume":"67","author":"A H\u00e4nninen","year":"2018","unstructured":"H\u00e4nninen, A. et al. Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut 67, 1445\u20131453 (2018).","journal-title":"Gut"},{"key":"564_CR53","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.chom.2022.03.030","volume":"30","author":"K Frazier","year":"2022","unstructured":"Frazier, K. et al. High-fat diet disrupts REG3\u03b3 and gut microbial rhythms promoting metabolic dysfunction. Cell Host Microbe 30, 809\u2013823.e806 (2022).","journal-title":"Cell Host Microbe"},{"key":"564_CR54","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nature25019","volume":"552","author":"NK Surana","year":"2017","unstructured":"Surana, N. K. & Kasper, D. L. Moving beyond microbiome-wide associations to causal microbe identification. Nature 552, 244\u2013247 (2017).","journal-title":"Nature"},{"key":"564_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-020-0785-4","volume":"8","author":"SR Bogatyrev","year":"2020","unstructured":"Bogatyrev, S. R., Rolando, J. C. & Ismagilov, R. F. Self-reinoculation with fecal flora changes microbiota density and composition leading to an altered bile-acid profile in the mouse small intestine. Microbiome 8, 19 (2020).","journal-title":"Microbiome"},{"key":"564_CR56","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.5166","volume":"6","author":"J Miyoshi","year":"2018","unstructured":"Miyoshi, J. et al. Minimizing confounders and increasing data quality in murine models for studies of the gut microbiome. PeerJ 6, e5166 (2018).","journal-title":"PeerJ"},{"key":"564_CR57","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2008","unstructured":"Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 22, 659\u2013661 (2008).","journal-title":"FASEB J."},{"key":"564_CR58","first-page":"1193","volume":"32","author":"J Miyoshi","year":"2012","unstructured":"Miyoshi, J. et al. 5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis. Anticancer Res. 32, 1193\u20131202 (2012).","journal-title":"Anticancer Res."},{"key":"564_CR59","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.celrep.2017.06.060","volume":"20","author":"J Miyoshi","year":"2017","unstructured":"Miyoshi, J. et al. Peripartum antibiotics promote gut dysbiosis, loss of immune tolerance, and inflammatory bowel disease in genetically prone offspring. Cell Rep. 20, 491\u2013504 (2017).","journal-title":"Cell Rep."},{"key":"564_CR60","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41587-019-0209-9","volume":"37","author":"E Bolyen","year":"2019","unstructured":"Bolyen, E. et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat. Biotechnol. 37, 852\u2013857 (2019).","journal-title":"Nat. Biotechnol."},{"key":"564_CR61","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","volume":"13","author":"BJ Callahan","year":"2016","unstructured":"Callahan, B. J. et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat. Methods 13, 581\u2013583 (2016).","journal-title":"Nat. Methods"},{"key":"564_CR62","doi-asserted-by":"publisher","first-page":"e0185056","DOI":"10.1371\/journal.pone.0185056","volume":"12","author":"B Bushnell","year":"2017","unstructured":"Bushnell, B., Rood, J. & Singer, E. BBMerge - accurate paired shotgun read merging via overlap. PLoS ONE 12, e0185056 (2017).","journal-title":"PLoS ONE"},{"key":"564_CR63","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"564_CR64","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/nar\/27.2.573","volume":"27","author":"G Benson","year":"1999","unstructured":"Benson, G. Tandem repeats finder: a program to analyze DNA sequences. Nucleic Acids Res. 27, 573\u2013580 (1999).","journal-title":"Nucleic Acids Res."},{"key":"564_CR65","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/s41587-023-01688-w","volume":"41","author":"A Blanco-M\u00edguez","year":"2023","unstructured":"Blanco-M\u00edguez, A. et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat. Biotechnol. 41, 1633\u20131644 (2023).","journal-title":"Nat. Biotechnol."},{"key":"564_CR66","doi-asserted-by":"publisher","first-page":"e1009442","DOI":"10.1371\/journal.pcbi.1009442","volume":"17","author":"H Mallick","year":"2021","unstructured":"Mallick, H. et al. Multivariable association discovery in population-scale meta-omics studies. PLoS Comput. Biol. 17, e1009442 (2021).","journal-title":"PLoS Comput. Biol."}],"container-title":["npj Biofilms and Microbiomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41522-024-00564-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41522-024-00564-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41522-024-00564-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T06:17:31Z","timestamp":1726467451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41522-024-00564-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["564"],"URL":"https:\/\/doi.org\/10.1038\/s41522-024-00564-y","relation":{},"ISSN":["2055-5008"],"issn-type":[{"value":"2055-5008","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"6 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M. has received grant support from AbbVie GK; and received consulting and lecture fees from EA Pharma Co., Ltd, AbbVie GK, Janssen Pharmaceutical K.K., Jansen Asia Pacific Pte. Ltd, Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, JIMRO Co., Miyarisan Co., Ltd, and Takeda Pharmaceutical Co., Ltd. M.M. has received consulting and lecture fees from Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd, AbbVie GK, Mitsubishi Tanabe Pharma Corporation, Kyorin Pharmaceutical Co., Ltd, Mochida Pharmaceutical Co., Ltd, JIMRO Co., Nippon Kayaku Co., Ltd, Mylan EPD G.K., and Aspen Japan Co., Ltd. T.H. has performed Joint Research with Alfresa Pharma Co., Ltd, and EA Pharma Co., Ltd; received grant support from AbbVie GK, Boston Scientific Corp., EA Pharma Co., Ltd, JIMRO Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd, Nippon Kayaku Co., Ltd, Pfizer Inc., and Takeda Pharmaceutical Co., Ltd, and received consulting and lecture fees from AbbVie GK, EA Pharma Co., Ltd, Janssen Research & Development, LLC., Gilead Sciences Inc., Eli Lilly and Co., Bristol Myers Squibb, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd, Mochida Pharmaceutical Co., Ltd, and Kissei Pharmaceutical Co., Ltd. All other authors declare no financial or non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}